<i>Chlamydia trachomatis</i>, <i>Neisseria gonorrhoeae</i> and human papillomavirus infections of lower genital tract of Indigenous women from Xingu Indigenous Park

Imagem de Miniatura
Arquivos
art_PORTO_iChlamydia_trachomatisi_iNeisseria_gonorrhoeaei_and_human_papillomavirus_infections_2023.PDF (846.28 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
COLL MEDICINE & DENTISTRY, JAMES COOK UNIV TOWNSVILLE
Autores
PORTO, Claudia Regina Cinti Correa
BONETTI, Tatiana C. S.
KAMAIURA, Sula Fernanda A.
DIAZ, Ricardo Sobhie
HEINKE, Thais
CURY, Fernanda de Paula
SANTANA, Iara Viana Vidigal
QUEIROZ, Mariana M.
Citação
RURAL AND REMOTE HEALTH, v.23, n.3, article ID 7126, 9p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Xingu Indigenous Park (XIP) currently protects 16 ethnic Indigenous groups and is located in the central area of Brazil. XIP is the first and the largest Indigenous land to be recognized in the country. Community access is limited and restricted for the non-Indigenous population, and the Indigenous women are constantly dealing with shortages of medical care. High-risk human papillomavirus (HR-HPV) is the most common cause of cervical cancer and is detected in 99% of cervical precancers. HPV infections may be associated with bacterial agents such as Chlamydia trachomatis and Neisseria gonorrhoeae, which are also important causative agents of sexually transmitted infections and are responsible for the most frequent bacterial infections in the world. The present study evaluated the frequency and potential impact of Chlamydia trachomatis, Neisseria gonorrhoeae, and HR-HPV in the Indigenous women of XIP. Methods: In this cross-sectional study, 992 cervical-vaginal samples were collected from Indigenous women, using a CervexBrush, and were immediately placed in a SurePath medium. All samples were submitted to the cobas & REG; 4800 detection system for the identification of 14 different types of HR-HPV, and the multiplex Abbott RealTime CT/NG assay for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae. Results: HR-HPV was detected in 18.2% of women; 6% were positive for HPV16, 5% for HPV18, and 81% for other types of HRHPV. Co-infections of HPV16 and other types was observed in 5% of women, and 3% had co-infections of HPV18 and other types. Moreover, 1.8% of women were positive for Chlamydia trachomatis, while Neisseria gonorrhoeae was not detected. In women with HR-HPV, 33% had Chlamydia trachomatis infections, 28% were positive for HR-HPV other than HPV16 or HPV18, and 5% had co-infections of HPV16 and the other types of HPV. Younger women were found to be more susceptible to HPV infections. Conclusion: The findings indicate a high frequency of HR-HPV and a considerable frequency of Chlamydia trachomatis in the Indigenous women of XIP. The detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and/or HR-HPV does not present evidence of a potential interrelationship for a combined pathogenic action in these women.
Palavras-chave
Brazil, Chlamydia trachomatis, HR-HPV, Indigenous women, Neisseria gonorrhoeae, sexually transmitted infections, Xingu Indigenous
URI
https://observatorio.fm.usp.br/handle/OPI/56328
Referências
  1. Adamson PC, 2020, J MOL DIAGN, V22, P811, DOI 10.1016/j.jmoldx.2020.03.004
  2. BC Center for Disease Control, 2003, ANN REP 2003
  3. Brazilian Institute of Geography and Statistics, 2021, DAT IND PEOPL QUIL 2
  4. Brazilian Institute of Geography and Statistics, 2021, RES POP ACC DOM STAT
  5. Brito EB, 2006, EUR J GYNAECOL ONCOL, V27, P279
  6. Centers for Disease Control and Prevention, 2021, NAT OV SEX TRANSM DI
  7. Centers for Disease Control and Prevention, 2021, STI TREATM GUID
  8. Chan CK, 2019, J ONCOL, V2019, DOI 10.1155/2019/3257939
  9. Cheng A, 2011, J CLIN MICROBIOL, V49, P1294, DOI 10.1128/JCM.02595-10
  10. Cluver C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010485.pub2
  11. Speck NMDG, 2009, EUR J GYNAECOL ONCOL, V30, P512
  12. Speck NMD, 2015, EINSTEIN-SAO PAULO, V13, P52, DOI 10.1590/S1679-45082015AO3222
  13. de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
  14. Dockterman J, 2021, PATHOG DIS, V79, DOI 10.1093/femspd/ftab012
  15. ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18
  16. Fernandes JV, 2009, INT J GYNECOL OBSTET, V105, P21, DOI 10.1016/j.ijgo.2008.12.004
  17. Freitas VG, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15036840
  18. Gabster A, 2021, SEX TRANSM INFECT, V97, P304, DOI 10.1136/sextrans-2019-054395
  19. Gabster A, 2019, SEX TRANSM DIS, V46, P780, DOI 10.1097/OLQ.0000000000001070
  20. Gannon-Loew KE, 2020, THER ADV INFECT DIS, V7, DOI 10.1177/2049936120960664
  21. Gaydos CA, 2010, J CLIN MICROBIOL, V48, P3236, DOI 10.1128/JCM.01019-10
  22. Graham S, 2012, MED J AUSTRALIA, V197, P642, DOI 10.5694/mja12.10163
  23. Han Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089658
  24. Ishak M O, 2001, Cad Saude Publica, V17, P385
  25. Jalil EM, 2008, REV BRAS GINECOL OBS, V30, P614, DOI 10.1590/S0100-72032008001200005
  26. Ji YP, 2019, J INFECT DIS, V219, P206, DOI 10.1093/infdis/jiy497
  27. Lemos PN, 2018, CAD SAUDE PUBLICA, V34, DOI [10.1590/0102-311x00079317, 10.1590/0102-311X00079317]
  28. Mark KS, 2019, CONT CLIN TRIAL COMM, V16, DOI 10.1016/j.conctc.2019.100414
  29. Martins TR, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0594-3
  30. Ministry of Health Brazil., 2004, NAT POL INT ATT WOM
  31. Ministry of Health of Brazil, 2015, CLIN PROT THER GUID
  32. Monsonego J, 2015, GYNECOL ONCOL, V137, P47, DOI 10.1016/j.ygyno.2015.01.551
  33. Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886
  34. National Cancer Institute Ministry of Health Brazil., 2021, IS THER VACC HPV
  35. Nonato DR, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.07.003
  36. Pereira ER, 2015, EUR J GYNAECOL ONCOL, V36, P376
  37. Risley C, 2020, CANCER CYTOPATHOL, V128, P528, DOI 10.1002/cncy.22267
  38. Robitaille A, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03573-8
  39. Scopin ACC, 2019, INVESTIGATIONS GYNEC, V3, P229
  40. Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI [10.3322/caac.21660, 10.3322/caac.21492]
  41. Torres-Ibarra L, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.15781
  42. Tso FK, 2015, GENET MOL RES, V14, P17630, DOI 10.4238/2015.December.21.36
  43. Weis B., 2011, SOCIAL ENV ALMANAC X
  44. World Health Organization, 2020, MULT RES GON
  45. World Health Organization Department of Reproductive Health and Research., 2011, PREVALENCE INCIDENCE
  46. World Health Organization Department of Reproductive Health and Research, 2012, GLOB ACT PLAN CONTR
  47. World Health Organzation, 2021, SEXUALLY TRANSMITTED

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/58
Artigos e Materiais de Revistas Científicas - ODS/03